These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 10901822)

  • 21. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AT(1)-receptor blockers: differences that matter.
    Gradman AH
    J Hum Hypertens; 2002 Aug; 16 Suppl 3():S9-S16. PubMed ID: 12140723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guidelines for the management of hypertension at primary health care level. Hypertension Society of Southern Africa, endorsed by the Medical Association of South Africa and the Medical Research Council.
    S Afr Med J; 1995 Dec; 85(12 Pt 2):1321-5. PubMed ID: 8600604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost implications of development of diabetes in the ALPINE study.
    Lindholm LH; Kartman B; Carlberg B; Persson M; Svensson A; Samuelsson O
    J Hypertens Suppl; 2006 Mar; 24(1):S65-72. PubMed ID: 16601576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers.
    Meredith PA
    Blood Press Suppl; 2001; (3):11-7. PubMed ID: 11683472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of published economic evaluations of angiotensin receptor blockers.
    Theodoratou D; Maniadakis N; Fragoulakis V; Stamouli E
    Hellenic J Cardiol; 2009; 50(2):105-18. PubMed ID: 19329412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Angiotensin II receptor antagonists: different or equivalent?].
    Mounier-Vehier C; Devos P
    Presse Med; 2001 Jun 16-23; 30(21):1072-5. PubMed ID: 11471284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between dose and antihypertensive effect for different AT1-receptor blockers.
    Hansson L
    Blood Press Suppl; 2001; (3):33-9. PubMed ID: 11683475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin Receptor Blockers Effect on Serum Uric Acid-A Class Effect?
    Sutton Burke EM; Kelly TC; Shoales LA; Nagel AK
    J Pharm Pract; 2020 Dec; 33(6):874-881. PubMed ID: 31390929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomic issues in antihypertensive therapy.
    Giles TD
    Am J Cardiol; 1999 Jul; 84(2A):25K-28K. PubMed ID: 10437741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The South African Hypertension Guideline 2006 is evidence-based and not cost-effective--a rebuttal.
    Rayner BL; Seedat YK; Milne J; Pinkney-Atkinson V; Veriava Y
    S Afr Med J; 2007 Mar; 97(3):152, 154. PubMed ID: 17440654
    [No Abstract]   [Full Text] [Related]  

  • 32. Antihypertensive drugs: a perspective on pharmaceutical price erosion and its impact on cost-effectiveness.
    Refoios Camejo R; McGrath C; Herings R; Meerding WJ; Rutten F
    Value Health; 2012; 15(2):381-8. PubMed ID: 22433771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomic considerations in the management of hypertension.
    Pardell H; Tresserras R; Armario P; Hernández del Rey R
    Drugs; 2000; 59 Suppl 2():13-20; discussion 39-40. PubMed ID: 10678593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of AT1 receptor blockers.
    Volmink J
    S Afr Med J; 2000 Dec; 90(12):1161-2. PubMed ID: 11234635
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pharmacoeconomic evaluation of hypothetical over-the-counter angiotensin-converting enzyme (ACE) inhibitors for the prevention of stroke in patients with grade I hypertension].
    Uchikura T; Yokoi N; Hashiguchi M; Mochizuki M
    Yakugaku Zasshi; 2011 Apr; 131(4):571-80. PubMed ID: 21467797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economics of antihypertensive therapy in the elderly.
    Dunn EC; Small RE
    Drugs Aging; 2001; 18(7):515-25. PubMed ID: 11482745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential economic impact of restricted access to angiotensin-receptor blockers.
    Guertin JR; Jackevicius CA; Cox JL; Humphries K; Pilote L; So DY; Tu JV; Wijeysundera H; Rinfret S;
    CMAJ; 2011 Feb; 183(3):E180-6. PubMed ID: 21262939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidelines for assessing outcomes of antihypertensive treatment.
    Weber M
    Am J Cardiol; 1999 Jul; 84(2A):2K-4K. PubMed ID: 10437736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension.
    Granström O; Levin LÅ; Henriksson M
    Clinicoecon Outcomes Res; 2012; 4():313-22. PubMed ID: 23144565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost Effectiveness Analysis of Candesartan Therapy in Comparison to Candesartan-Amlodipine Therapy on Hypertensive Outpatients.
    Baroroh F; Sari A; Masruroh N
    Open Access Maced J Med Sci; 2019 Nov; 7(22):3837-3840. PubMed ID: 32127987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.